Fore Capital, LLC Precigen, Inc. Transaction History

Fore Capital, LLC

$117 Million
Q2 2024

A detailed history of Fore Capital, LLC transactions in Precigen, Inc. stock. As of the latest transaction made, Fore Capital, LLC holds 206,811 shares of PGEN stock, worth $169,585. This represents 0.28% of its overall portfolio holdings.

Number of Shares

206,811

Previous 306,791 32.59%

Holding current value

$169,585

Previous $444,000 26.58%

% of portfolio

0.28%

Previous 0.36%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	SELL	$1.27 - $1.75 $126,974 - $174,965	-99,980 Reduced 32.59%	206,811 $326,000
Q1 2024 May 07, 2024	SELL	$1.21 - $1.75 $60,500 - $87,500	-50,000 Reduced 14.01%	306,791 $444,000
Q4 2023 Feb 13, 2024	SELL	$0.89 - $1.41 $62,300 - $98,700	-70,000 Reduced 16.4%	356,791 $478,000
Q3 2023 Nov 06, 2023	SELL	$1.08 - $1.85 $68,265 - $116,936	-63,209 Reduced 12.9%	426,791 $606,000
Q1 2023 May 09, 2023	BUY	$0.88 - $2.19 $338,800 - $843,150	385,000 Added 366.67%	490,000 $519,000
Q4 2022 Feb 13, 2023	SELL	$1.27 - $2.26 $114,300 - $203,399	-90,000 Reduced 46.15%	105,000 $159,000
Q3 2022 Nov 10, 2022	SELL	$1.41 - $2.79 $141,000 - $279,000	-100,000 Reduced 33.9%	195,000 $413,000
Q2 2022 Aug 08, 2022	BUY	$1.15 - $2.53 $184,000 - $404,799	160,000 Added 118.52%	295,000 $395,000
Q1 2022 May 11, 2022	BUY	$1.91 - $3.98 $257,850 - $537,300	135,000 New	135,000 $285,000
Q3 2021 Nov 12, 2021	SELL	$4.99 - $6.55 $49,900 - $65,500	-10,000 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$6.24 - $8.22 $62,400 - $82,200	10,000 New	10,000 $65,000
Q2 2020 Aug 13, 2020	SELL	$2.16 - $5.46 $60,588 - $153,153	-28,050 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.46 - $7.19 $40,953 - $201,679	28,050 New	28,050 $95,000

Others Institutions Holding PGEN

# of Institutions

140

Shares Held

145M

Call Options Held

292K

Put Options Held

53.8K

View Full List

About PRECIGEN, INC.

Ticker PGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 208,150,000
Market Cap $171M
Description
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorpora...

More about PGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fore Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fore Capital, LLC with notifications on news.

Account